Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Benzodiazepines, OTCs Are As Effective As Newer Rx Sleep Agents - Article

  • News

Executive Summary

Newer insomnia treatments are no more effective than benzodiazepines and OTC antihistamines, Consumer Reports' August 2006 "Best Buy Drugs" report says

You may also be interested in...



Long-Acting Overactive Bladder Drugs Have Less Risk – Consumer Reports

Extended-release forms of overactive bladder drugs have better side effect profiles than their shorter-acting counterparts, according to Consumer Reports September 2006 "Best Buy Drugs.

Long-Acting Overactive Bladder Drugs Have Less Risk – Consumer Reports

Extended-release forms of overactive bladder drugs have better side effect profiles than their shorter-acting counterparts, according to Consumer Reports September 2006 "Best Buy Drugs.

Pfizer Drops Out Of Indiplon Development; Neurocrine To Seek New Partner

Neurocrine will seek a new commercialization partner for the insomnia agent indiplon following Pfizer's decision to exit a collaboration for the drug, CEO Gary Lyons said during a June 22 conference call

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By